ADAR1 and ZBP1 in Breast Cancer: Pathological Mechanism and Therapeutics
DOI:
https://doi.org/10.54097/fr2bb227Keywords:
ADAR1, ZBP1, Breast Cancer, Cell DeathAbstract
Breast cancer is a heterogeneous disease in which a variety of genetic and environmental factors are involved. Among them, adenosine deaminase acting on RNA 1 (ADAR1) and Z-DNA binding protein 1 (ZBP1) are the factors that have opposite functions in the process of regulating cell viability as well as inflammatory and immunity. Recently, the two factors have been proved to act as a key player in caspase-8-dependent PANotosis and IFN-γ-dependent immunoregulation in the development of most types of cancers. In this review, we discuss the basic functions of ADAR1 and ZBP1 as well as the interactions between them in regulating innate immune responses in breast cancer therapeutics.
Downloads
References
[1] Lei, Y., VanPortfliet, J. J., Chen, Y. F., Bryant, J. D., Li, Y., Fails, D., ... & West, A. P. (2023). Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity. Cell.
[2] Lee, S., Karki, R., Wang, Y., Nguyen, L. N., Kalathur, R. C., & Kanneganti, T. D. (2021). AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature, 597 (7876), 415-419.
[3] Karki, R., Lee, S., Mall, R., Pandian, N., Wang, Y., Sharma, B. R., ... & Kanneganti, T. D. (2022). ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. Science immunology, 7(74), eabo6294.
[4] Nassour, J., Aguiar, L. G., Correia, A., Schmidt, T. T., Mainz, L., Przetocka, S., ... & Karlseder, J. (2023). Telomere-to-mitochondria signalling by ZBP1 mediates replicative crisis. Nature, 614(7949), 767-773.
[5] Zhang, T., Yin, C., Fedorov, A., Qiao, L., Bao, H., Beknazarov, N., ... & Balachandran, S. (2022). ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature, 606(7914), 594-602.
[6] Karki R, Kanneganti TD. ADAR1 and ZBP1 in innate immunity, cell death, and disease. Trends Immunol. 2023 Mar;44(3):201-216. doi: 10.1016/j.it.2023.01.001. Epub 2023 Jan 27. PMID: 36710220; PMCID: PMC9974732.
[7] Kuriakose, T., & Kanneganti, T. D. (2018). ZBP1: innate sensor regulating cell death and inflammation. Trends in Immunology, 39(2), 123-134.
[8] Karki, R., Sundaram, B., Sharma, B. R., Lee, S., Malireddi, R. S., Nguyen, L. N., ... & Kanneganti, T. D. (2021). ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis. Cell reports, 37(3).
[9] Zhang, T., Yin, C., Boyd, D. F., Quarato, G., Ingram, J. P., Shubina, M., ... & Balachandran, S. (2020). Influenza virus Z-RNAs induce ZBP1-mediated necroptosis. Cell, 180(6), 1115-1129.
[10] Chung, H., Calis, J. J., Wu, X., Sun, T., Yu, Y., Sarbanes, S. L., ... & Rice, C. M. (2018). Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell, 172(4), 811-824.
[11] Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., ... & Campbell, P. J. (2012). The life history of 21 breast cancers. Cell, 149(5), 994-1007.
[12] Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. Cell, 140(6), 805-820.
[13] Zheng, M., Karki, R., Vogel, P., & Kanneganti, T. D. (2020). Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. Cell, 181(3), 674-687.
[14] Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., ... & Zhao, J. J. (2015). CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell, 163(1), 174-186.
[15] Wang, H., Xiang, D., Liu, B., He, A., Randle, H. J., Zhang, K. X., ... & Livingston, D. M. (2019). Inadequate DNA damage repair promotes mammary transdifferentiation, leading to BRCA1 breast cancer. Cell, 178(1), 135-151.
[16] Krug, K., Jaehnig, E. J., Satpathy, S., Blumenberg, L., Karpova, A., Anurag, M., ... & Zimmerman, L. J. (2020). Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell, 183(5), 1436-1456.
[17] Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A., ... & Haining, W. N. (2019). Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature, 565(7737), 43-48.
[18] Herbert, A., & Balachandran, S. (2022). Z-DNA enhances immunotherapy by triggering death of inflammatory cancer-associated fibroblasts. Journal for Immunotherapy of Cancer, 10(11).
[19] Zhao, F., Zhao, C., Xu, T., Lan, Y., & Li, X. (2023). Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy. Frontiers in Immunology, 14, 1245514.
[20] Wang, X., Tokheim, C., Gu, S. S., Wang, B., Tang, Q., Li, Y., ... & Liu, X. S. (2021). In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell, 184(21), 5357-5374.
[21] Samir, P., Malireddi, R. S., & Kanneganti, T. D. (2020). The PANoptosome: a deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis). Frontiers in cellular and infection microbiology, 10, 238.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
